136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

M. J. Ahn; J. Yang; H. Yu; H. Saka; S. Ramalingam; K. Goto; S. W. Kim; L. Yang; A. Walding; G. R. Oxnard

doi:10.1016/S1556-0864(16)30246-5

136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

M. J. Ahn
, J. Yang
, H. Yu
, H. Saka
, S. Ramalingam
, K. Goto
, S. W. Kim
, L. Yang
, A. Walding
, G. R. Oxnard

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S115
Journal	Journal of Thoracic Oncology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1016/S1556-0864(16)30246-5
Publication status	Published - 04-2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/S1556-0864(16)30246-5

Cite this

@article{b40238d2b5d540eea805caa8191a84b7,

title = "136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial",

author = "Ahn, \{M. J.\} and J. Yang and H. Yu and H. Saka and S. Ramalingam and K. Goto and Kim, \{S. W.\} and L. Yang and A. Walding and Oxnard, \{G. R.\}",

year = "2016",

month = apr,

doi = "10.1016/S1556-0864(16)30246-5",

language = "English",

volume = "11",

pages = "S115",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - 136O

T2 - Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

AU - Ahn, M. J.

AU - Yang, J.

AU - Yu, H.

AU - Saka, H.

AU - Ramalingam, S.

AU - Goto, K.

AU - Kim, S. W.

AU - Yang, L.

AU - Walding, A.

AU - Oxnard, G. R.

PY - 2016/4

Y1 - 2016/4

UR - https://www.scopus.com/pages/publications/85040257501

UR - https://www.scopus.com/pages/publications/85040257501#tab=citedBy

U2 - 10.1016/S1556-0864(16)30246-5

DO - 10.1016/S1556-0864(16)30246-5

M3 - Article

AN - SCOPUS:85040257501

SN - 1556-0864

VL - 11

SP - S115

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 4

ER -

136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this